Nolvadex (Tamoxifen) an Antioestrogen of Potential Use in the Management of Carcinoma of the Prostate
Well-differentiated prostatic cancer cells, like normal prostatic cells, remain for a time, androgen-dependent. Oestrogens in sufficient dosage reduce circulating androgens, and this has been the rationale for conventional oestrogen therapy. At least 3 mg. daily of Stilboestrol, in divided doses, are needed to suppress plasma testosterone levels throughout 24 hours (1,2), but clinically 1 mg. per day is as effective in controlling the disease (3). This therapeutic evidence for an additional direct action of oestrogens upon the prostate is supported by the classical animal experiments of Huggins and Clark in 1940 (4) and by the tissue culture studies of Earnsworth (5).
KeywordsPlasma Testosterone Level Tissue Culture Study Hormone Dependent Breast Cancer Secondary Rise Objective Partial Response
Unable to display preview. Download preview PDF.
- 5.W.E. Farnsworth, The Normal Prostate and Its Endocrine Control, in “The Third Tenovus Workshop — Some Aspects of the Aetiology and Biochemistry of Prostatic Cancer”, K. Griffith and C.G. Pierrpoint (eds), Alpha Omega Ltd., Cardiff (1970) p. 3.Google Scholar
- 14.J.L. Williams, Personal Communication (1980).Google Scholar
- 15.L.R. Morgan, L.E. Posey and J. Lanasa, Therapeutic Use of Nolvadex (Tamoxifen ICI 46, 4741) in Advanced Prostatic Cancer, Proc. of 12. Int. Cancer Congress, Beunos Aires, 5–11 October 1978, W51 page 111, Abstract 17.Google Scholar
- 17.W.B. Pratt and R.W. Ruddon, “The Anticancer Drugs, Oxford University Press, (1979) p. 212.Google Scholar